Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of urothelial bladder cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Optimize the current and future management of high-risk non-muscle-invasive bladder cancer that is unresponsive to BCG, considering the efficacy and tolerability of novel intravesical and systemic therapies.
• Appreciate the biological rationale for combining anti-PD-1/PD-L1 antibodies with chemotherapy or other systemic agents with established efficacy for urothelial bladder cancer (UBC), such as antibody-drug conjugates, and assess the current role of these regimens in patient care.
• Develop an understanding of available clinical trial findings with HER2-directed therapies for advanced UBC, and evaluate the current and future utility of these agents in the clinical care of appropriately selected patients.
• Assess the biological rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for patients with non-muscle-invasive bladder cancer, muscle-invasive bladder cancer and metastatic UBC.

CME Credit Form
A CME credit form link will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Galsky — Advisory Committees: AbbVie Inc, Aktis Oncology, Alligator Bioscience, Analog Devices Inc, Asieris Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bicycle Therapeutics, Bristol Myers Squibb, Curis Inc, Daiichi Sankyo Inc, Dragonfly Therapeutics, EMD Serono Inc, FUJIFILM Pharmaceuticals USA Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Merck, Numab Therapeutics AG, Pfizer Inc, Rappta Therapeutics, Seagen Inc, Silverback Therapeutics, UroGen Pharma, Veracyte Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Merck, Novartis. Dr Kamat — Advisory Committees and Consulting Agreements: Astellas, Biological Dynamics, Bristol Myers Squibb, CG Oncology, Cystotech, Eisai Inc, enGene, Ferring Pharmaceuticals, Imagin Medical, Imvax Inc, Incyte Corporation, Janssen Biotech Inc, Medac, Merck, Nonagen Bioscience, Pfizer Inc, Photocure, Protara Therapeutics, Roche Laboratories Inc, Seagen Inc, Sesen Bio, Theralase, UroGen Pharma, US Biotest Inc, Vivet Therapeutics; Contracted Research: Arquer Diagnostics, enGene, Ferring Pharmaceuticals, Photocure, Seagen Inc; Data and Safety Monitoring Board/Committee: Seagen Inc; Nonrelevant Financial Relationships: Patient-Centered Outcomes Research Institute, SWOG.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporter
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.